Silence Therapeutics (SLN) AI Stock Analysis

• Market Cap: $243.73M
• Dividend Yield: N/A
• Average Volume (3M): 73.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: -40.10%
• EPS Growth: -16.60%
• Country: US
• Employees: 116
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 47,233,948
• 10 Day Avg. Volume: 65,787
• 30 Day Avg. Volume: 73,323
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.66
• Enterprise Value/Revenue: 6.18
• Enterprise Value/Gross Profit: 7.50
• Enterprise Value/Ebitda: -2.83
• 1Y Price Target: $30.13
• Price Target Upside: 479.42% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 49 Neutral
• Price Target: $5.50 ▲(5.77% Upside)

Silence Therapeutics faces significant financial challenges, with negative equity and cash flow issues being the most critical. Technical indicators suggest a mixed outlook, with short-term bearish trends. The company's strategic governance improvements provide some positive outlook, but the overall financial instability remains a major concern.

Positive Factors

Clinical Program Advancements

Silence Therapeutics is advancing its clinical programs with divesiran showing strong potential in controlling polycythemia vera without the need for phlebotomy.

Financial Stability

Silence Therapeutics has a cash runway extending into 2028, providing financial stability to focus on high-value programs and sustained value creation.

Market Opportunities

Despite PV's increasingly crowded landscape, PV remains a large commercial opportunity given the high unmet need and significant sales potential.

Negative Factors

Competitive Landscape

Despite PV's increasingly crowded landscape, PV remains a large commercial opportunity given high unmet need, evidenced by significant sales and partnerships.

Partnership Uncertainty

The start of a Ph3 cardiovascular outcomes study (CVOT) for zerlasiran will depend on securing a partner.

Valuation Concerns

Shares currently do not reflect any value for zerlasiran as partnering discussions remain ongoing.

Silence Therapeutics Business Overview & Revenue Model

Company Description

Silence Therapeutics (SLN) is a biotechnology company focused on the discovery, development, and delivery of novel RNA therapeutics. The company operates in the biopharmaceutical and life sciences sectors, leveraging its proprietary mRNAi GOLD™ platform to develop medicines that can selectively inhibit the expression of disease-causing genes. Silence Therapeutics' core products are primarily in the areas of cardiovascular, hematology, and rare diseases, aiming to address significant unmet medical needs.

How the Company Makes Money

Silence Therapeutics generates revenue through a combination of research and development collaborations, licensing agreements, and milestone payments from its partnerships with other pharmaceutical and biotech companies. The company licenses its proprietary RNA interference technology to partners who utilize it in the development of their own drug candidates. Additionally, Silence Therapeutics may earn royalties from successfully commercialized products that incorporate its technology. Key partnerships with industry leaders contribute significantly to its earnings by providing upfront payments, research funding, and potential future royalties based on product sales. The company's financial model heavily relies on its ability to establish and maintain strategic alliances that leverage its innovative platform.

Silence Therapeutics Financial Statement Overview

Summary

Silence Therapeutics shows revenue growth but struggles with profitability, negative equity, and cash flow challenges. The financial instability is a significant concern, requiring strategic improvements in cost management and financial planning.

Income Statement

Silence Therapeutics has demonstrated significant revenue growth over the years, with a notable increase from 2023 to 2024. However, the company continues to face challenges with profitability, as evidenced by negative EBIT and net income margins. The consistent negative profit margins highlight a need for enhanced cost management or increased revenue to achieve profitability.

Balance Sheet

The company's balance sheet reveals a concerning negative stockholders' equity as of 2024, indicating financial instability. The debt-to-equity ratio is not favorable due to the negative equity, and although the company maintains substantial cash reserves, the high liabilities present a risk. Improving equity and managing liabilities are critical for financial health.

Cash Flow

Silence Therapeutics has managed significant financing cash flow, which supports its operations despite negative operating cash flow. The free cash flow has been consistently negative, reflecting ongoing cash challenges. However, the company's ability to secure financing offers some operational flexibility. Improving free cash flow is essential for sustainable growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	25.84M	43.26M	25.38M	17.50M	12.41M	5.48M
Gross Profit	21.32M	31.45M	15.06M	6.62M	4.96M	1.72M
EBITDA	-56.55M	-48.99M	-49.78M	-47.88M	-45.42M	-35.53M
Net Income	-68.72M	-45.31M	-43.27M	-40.49M	-39.41M	-32.55M
Balance Sheet
Total Assets	165.23M	202.63M	93.82M	107.50M	96.19M	85.97M
Cash, Cash Equivalents and Short-Term Investments	114.16M	147.33M	54.03M	71.14M	73.54M	37.45M
Total Debt	0.00	117.00K	272.00K	446.00K	137.00K	341.00K
Total Liabilities	71.08M	68.61M	76.77M	85.43M	87.67M	76.91M
Stockholders Equity	94.16M	134.02M	17.05M	22.07M	8.53M	9.06M
Cash Flow
Free Cash Flow	-78.77M	-67.85M	-39.40M	-45.90M	5.47M	-11.29M
Operating Cash Flow	-78.61M	-67.64M	-39.35M	-45.46M	6.81M	-10.78M
Investing Cash Flow	-6.66M	-21.97M	16.43M	-16.54M	8.68M	9.62M
Financing Cash Flow	25.86M	142.09M	25.16M	43.05M	30.71M	15.43M

Silence Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLN, the sentiment is Negative. The current price of 5.2 is below the 20-day moving average (MA) of 5.49, below the 50-day MA of 5.81, and below the 200-day MA of 5.64, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 41.75 is Neutral, neither overbought nor oversold. The STOCH value of 21.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLN.

Silence Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADCT	54 Neutral	$356.62M	―	123.38%	―	15.73%	38.73%
RGLS	52 Neutral		―		―	―	44.85%
FDMT	52 Neutral	$304.97M	―	-38.87%	―	―	―
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
SLN	49 Neutral	$243.73M	―	-99.23%	―	-40.10%	-16.60%
KRRO	45 Neutral	$190.26M	―	-58.34%	―	―	61.73%
KLRS	28 Underperform	$42.85M	―	-50.68%	―	―	73.18%

Silence Therapeutics Corporate Events

Michael Davidson Resigns from Silence Therapeutics Board

On August 11, 2025, Michael Davidson resigned from the board of directors of Silence Therapeutics plc to focus on his role as CEO of NewAmsterdam Pharma Company N.V. His departure was not due to any disagreements with the company. The board expressed gratitude for his contributions and reduced its size from five to four directors, appointing Iain Ross to fill the vacancy on the Audit and Risk Committee.

Silence Therapeutics Passes Key Resolutions at AGM

On June 26, 2025, Silence Therapeutics held its Annual General Meeting where all thirteen proposed resolutions were passed. Key decisions included the reappointment of directors, approval of executive compensation on an annual basis, and the ratification of PricewaterhouseCoopers LLP as auditors. These resolutions reflect the company’s strategic focus on governance and financial oversight, potentially strengthening its operational stability and stakeholder confidence.